SMIM26

Across TCGA pan-cancer cohorts, SMIM26 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMIM26 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SMIM26 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMIM26 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where SMIM26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	1.000	0.696	.005	16	view →
CCRCC	DFS	Tertile	IV	0.198	0.887	.024	13	view →
LUAD	DFS	Quartile	All	0.473	0.862	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SMIM26–GBM (OS)

Open the GBM breakdown →